Biogen’s Phase II Lupus Success Offers An Additional Viable Pipeline Asset
Executive Summary
While Biogen is seeking to diversify its R&D efforts, unexpected good data in two forms of lupus make internally discovered BIIB059 a viable asset to take forward, although Phase III plans are not set.